Perceval Sutureless Aortic Valve meta analysis is reviewed in Innovations highlighting Perceval as a safe aortic valve replacement option.- LivaNova

LivaNova PLC announced the publication of the analysis, �The Perceval Sutureless Aortic Valve: Review of Outcomes, Complications and Future Direction,� by Powell, Pelletier, Chu, Bouchard, Melvin and Adams in the latest issue of Innovations. The literature review, which included a meta-analysis of 89 studies, highlighted Perceval as a safe aortic valve replacement option that provides a shorter procedure and recovery time along with favorable hemodynamics for patients. The results of this literature review and meta-analysis demonstrated a statistically significant reduction in aortic cross-clamp and cardiopulmonary bypass times with Perceval when compared to stented biological aortic valves.

Perceval provided safe clinical and hemodynamic outcomes, and showed a statistically significant reduction in paravalvular leakage and early mortality. Further, the survival rate was statistically significantly higher for Perceval in two studies when compared to transcatheter aortic valve implantation. An analysis of 17 single-arm studies showed that the 30-day mortality rate ranged from 0% to 4.9%, while the five-year survival rate ranged from 71.31% to 85.5% with Perceval . As a truly sutureless aortic valve, Perceval has been shown to improve patient outcomes by providing reduced procedure time, minimizing postoperative complications, enabling shorter hospital stays and reducing the overall cost compared to traditional sutured valves.

Engineered to restore natural valve performance, the Perceval valve features a super-elastic stent, which is able to adapt to the movement of the aorta during the cardiac cycle. Including the period of clinical studies, the Perceval sutureless valve has been in use for a decade and has been implanted in more than 25,000 patients.

See- Powell R, Pelletier MP, Chu MWA, Bouchard D, Melvin KN, Adams C. Innovations 2017 May/Jun;12(3):155-173.